2021 APSC共识建议：直接口服抗凝药在亚洲房颤患者中的应用

2021-05-28 Eur Cardiol.2021 May 28;16:e23.

2021年5月，亚太心脏病学会(APSC)发布了直接口服抗凝药在亚洲房颤患者中的应用共识建议。亚太地区房颤患者的疾病负担比世界其他地区更重。直接口服抗凝药（DOACs）已经成为房颤患者预防血栓栓塞事件

中文标题：

英文标题：

Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management

发布机构：

发布日期：

2021-05-28

简要介绍：

2021年5月，亚太心脏病学会(APSC)发布了直接口服抗凝药在亚洲房颤患者中的应用共识建议。亚太地区房颤患者的疾病负担比世界其他地区更重。直接口服抗凝药（DOACs）已经成为房颤患者预防血栓栓塞事件中维生素K拮抗剂的有效替代品。本文主要针对直接口服抗凝药在亚洲房颤患者中的应用提供共识指导。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=5f0031c002122add, title=2021 APSC共识建议：直接口服抗凝药在亚洲房颤患者中的应用, enTitle=Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management, guiderFrom=Eur Cardiol.2021 May 28;16:e23., authorId=0, author=, summary=2021年5月，亚太心脏病学会(APSC)发布了直接口服抗凝药在亚洲房颤患者中的应用共识建议。亚太地区房颤患者的疾病负担比世界其他地区更重。直接口服抗凝药（DOACs）已经成为房颤患者预防血栓栓塞事件, cover=https://img.medsci.cn/2021630/1625066449168_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri May 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年5月，亚太心脏病学会(APSC)发布了直接口服抗凝药在亚洲房颤患者中的应用共识建议。亚太地区房颤患者的疾病负担比世界其他地区更重。直接口服抗凝药（DOACs）已经成为房颤患者预防血栓栓塞事件中维生素K拮抗剂的有效替代品。本文主要针对直接口服抗凝药在亚洲房颤患者中的应用提供共识指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=3159, tagName=口服抗凝药)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3159, guiderKeyword=口服抗凝药, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4646, appHits=308, showAppHits=0, pcHits=1140, showPcHits=4338, likes=1, shares=22, comments=24, approvalStatus=1, publishedTime=Wed Jun 30 23:53:41 CST 2021, publishedTimeString=2021-05-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 30 23:21:55 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 07:38:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 APSC共识建议：直接口服抗凝药在亚洲房颤患者中的应用.pdf)])

2021 APSC共识建议：直接口服抗凝药在亚洲房颤患者中的应用.pdf

下载请点击：

评论区 (21)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1224181, encodeId=c1df122418163, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f97cc55a186648a2b2b23983accd4506/e579f1acfec94536bb71c805c6406334.jpg, createdBy=5ecc4170607, createdName=小军2021, createdTime=Thu Jun 02 23:41:29 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205332, encodeId=26ef1205332e0, content=学习了有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=473c5555915, createdName=ms9000001386231029, createdTime=Wed Mar 23 20:10:36 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203895, encodeId=f6ea12038953d, content=学习刚好有用到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:14:25 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080577, encodeId=eb6010805e781, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:06:37 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080569, encodeId=74cf108056946, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:05:16 CST 2021, time=2021-12-16, status=1, ipAttribution=)]
2022-06-02 小军2021

学习了

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1224181, encodeId=c1df122418163, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f97cc55a186648a2b2b23983accd4506/e579f1acfec94536bb71c805c6406334.jpg, createdBy=5ecc4170607, createdName=小军2021, createdTime=Thu Jun 02 23:41:29 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205332, encodeId=26ef1205332e0, content=学习了有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=473c5555915, createdName=ms9000001386231029, createdTime=Wed Mar 23 20:10:36 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203895, encodeId=f6ea12038953d, content=学习刚好有用到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:14:25 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080577, encodeId=eb6010805e781, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:06:37 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080569, encodeId=74cf108056946, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:05:16 CST 2021, time=2021-12-16, status=1, ipAttribution=)]
2022-03-23 ms9000001386231029

学习了有用

39 0
[GetPortalCommentsPageByObjectIdResponse(id=1224181, encodeId=c1df122418163, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f97cc55a186648a2b2b23983accd4506/e579f1acfec94536bb71c805c6406334.jpg, createdBy=5ecc4170607, createdName=小军2021, createdTime=Thu Jun 02 23:41:29 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205332, encodeId=26ef1205332e0, content=学习了有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=473c5555915, createdName=ms9000001386231029, createdTime=Wed Mar 23 20:10:36 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203895, encodeId=f6ea12038953d, content=学习刚好有用到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:14:25 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080577, encodeId=eb6010805e781, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:06:37 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080569, encodeId=74cf108056946, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:05:16 CST 2021, time=2021-12-16, status=1, ipAttribution=)]
2022-03-18 17326332

学习刚好有用到

47 0
[GetPortalCommentsPageByObjectIdResponse(id=1224181, encodeId=c1df122418163, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f97cc55a186648a2b2b23983accd4506/e579f1acfec94536bb71c805c6406334.jpg, createdBy=5ecc4170607, createdName=小军2021, createdTime=Thu Jun 02 23:41:29 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205332, encodeId=26ef1205332e0, content=学习了有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=473c5555915, createdName=ms9000001386231029, createdTime=Wed Mar 23 20:10:36 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203895, encodeId=f6ea12038953d, content=学习刚好有用到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:14:25 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080577, encodeId=eb6010805e781, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:06:37 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080569, encodeId=74cf108056946, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:05:16 CST 2021, time=2021-12-16, status=1, ipAttribution=)]
2021-12-16 龙珠

好资料

53 0
[GetPortalCommentsPageByObjectIdResponse(id=1224181, encodeId=c1df122418163, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f97cc55a186648a2b2b23983accd4506/e579f1acfec94536bb71c805c6406334.jpg, createdBy=5ecc4170607, createdName=小军2021, createdTime=Thu Jun 02 23:41:29 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205332, encodeId=26ef1205332e0, content=学习了有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=473c5555915, createdName=ms9000001386231029, createdTime=Wed Mar 23 20:10:36 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203895, encodeId=f6ea12038953d, content=学习刚好有用到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:14:25 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080577, encodeId=eb6010805e781, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:06:37 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080569, encodeId=74cf108056946, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:05:16 CST 2021, time=2021-12-16, status=1, ipAttribution=)]
2021-12-16 龙珠

好资料

39 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021 APSC共识建议：直接口服抗凝药在亚洲房颤患者中的应用

相关指南

拓展阅读

科室

工具

服务